Signal Detection of DPP-IV Inhibitors using Spontaneous Adverse Event Reporting System in Korea
10.24304/kjcp.2024.34.2.100
- Author:
Hyejung PYO
1
;
Tae Young KIM
;
Su Been CHOI
;
Hyeong Jun JO
;
Hae Lee KANG
;
Jung Sun KIM
;
Hye Sun GWAK
;
Ji Min HAN
Author Information
1. College of Pharmacy and the Graduate School of Converging Clinical & Public Health, Ewha Womans University, Seoul 03760, Republic of Korea
- Publication Type:Original Article
- From:Korean Journal of Clinical Pharmacy
2024;34(2):100-107
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:The purpose of this study was to detect signals of adverse events (AEs) of DPP-IV inhibitors using the KIDs-Korea Adverse Event Reporting System (KAERS) database.
Methods:This study was conducted using AEs reported from January 2009to December 2018 in the KIDs-KAERS database. For signal detection, disproportionality analysis was performed. Signals of DPPIV inhibitor that satisfied the data-mining indices of reporting odds ratio (ROR) were detected.
Results:Among the total number of 10,364 AEs to all oral hypoglycemic agents, the number of reported AEs related to DPP-IV inhibitors was 1,674. Analysis of re-ported AEs of DPP-IV inhibitors at the SOC levels showed that Respiratory system disorders were the highest at 4.31 (95% CI 3.01-6.17), followed by Skin and appendages disorders at 2.04 (95% CI 1.74-2.38). When analyzing AEs reported at the PT level, phar-yngitis was the highest at 73.90 (95% CI 17.59-310.49), followed by arthralgia at 6.08 (95% CI 2.04-18.11), and coughing at 5.21 (95% CI 2.07-13.15).
Conclusions:Based on the result of the study, deeper consideration is required according to the characteristics of the patients in prescribing DPP-IV inhibitors among oral hypoglycemic agents, and continuous monitoring of the occurrence of related Adverse Drug Reactions during administration is also required.
